The NeoTYPE® Gastric Tumor Profile analyzes 39 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, reflex to either NTRK NGS Fusion Panel (Default) or NTRK 1-3 FISH Panel will be added. A microsatellite instability (MSI) NGS result of "indeterminate" will create a reflex to MSI by PCR as long as the tumor percentage is ≥40% and paired normal tissue is available. NGS (33 genes + 2 biomarkers): AKT1, ARID1A, BRAF, CDH1, CDKN2A, EGFR, ERBB2, ERBB3, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), MLH1, MSH2, MSH6, NOTCH1, NRAS, PDGFRA, PIK3CA, PMS2, PREX2, PTEN, RNF43, SMAD4, SMO, SRC, TGFBR2, TERT Promoter, TP53, Tumor Mutation Burden (TMB) FISH (2 FISH): MET, PTEN (tech-only available) IHC (6 biomarkers): MMR (opt-out available), PD-L1 22C3, Pan-TRK (tech-only available for MMR and PD-L1).